Atabecestat development was halted after liver toxicity signals, separating BACE1 target engagement from acceptable translational safety.

Evidence span

Atabecestat development was halted after liver toxicity signals, separating BACE1 target engagement from acceptable translational safety.

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Preclinical or early Alzheimer's disease risk populations treated with a BACE inhibitor; liver safety monitoring.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required